VRC 016

Principal Investigator(s):Julie E Ledgerwood, D.O.
Objective:To evaluate Early Innate and Adaptive Immune Responses to the Investigational HIV-1 Vaccines: VRC-HIVADV014-00-VP and VRC-HIVDNA016-00-VP in Ad5 Seronegative Healthy Adults.
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Open label, Randomized
Arms and Assigned Interventions
Descriptionmg dose in a 1 mL volume administered intramuscularly (IM) by Biojector (registered trademark) into deltoid muscle.
Mode of DeliveryIntramuscular
Official Code: NCT01386489
Trial Sponsors: NIAID
Start Date
End Date
June 1, 2011
March 31, 2014
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women